Shandong Weigao Group Medical Polymer Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Rinan Cong
Algemeen directeur
CN¥4.0m
Totale compensatie
| Percentage CEO-salaris | 42.1% |
| Dienstverband CEO | no data |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 2.4yrs |
| Gemiddelde ambtstermijn bestuur | 2.4yrs |
Recente managementupdates
Recent updates
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
Nov 26
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital
Nov 04Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥4m | CN¥2m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥5m | CN¥950k | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥2b |
| Dec 31 2021 | CN¥3m | CN¥903k | CN¥2b |
Compensatie versus markt: De totale vergoeding ($USD 550.36K ) Rinan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 505.95K ).
Compensatie versus inkomsten: De vergoeding van Rinan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Rinan Cong (43 yo)
no data
Tenure
CN¥3,990,000
Compensatie
Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.9yrs | CN¥8.27m | 0.14% HK$ 29.2m | |
| Chief Executive Officer | no data | CN¥3.99m | 0.048% HK$ 9.9m | |
| Executive Director | 2.4yrs | CN¥1.32m | geen gegevens | |
| Chief Financial Officer | 7.8yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Executive Director | less than a year | geen gegevens | 0.011% HK$ 2.3m | |
| Company Secretary | 18.5yrs | geen gegevens | geen gegevens |
2.4yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1066 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.9yrs | CN¥8.27m | 0.14% HK$ 29.2m | |
| Executive Director | 2.4yrs | CN¥1.32m | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Executive Director | less than a year | geen gegevens | 0.011% HK$ 2.3m | |
| Non-Executive Director | 3.7yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 2.2yrs | CN¥150.00k | geen gegevens | |
| Independent Non-Executive Director | 2.4yrs | CN¥207.00k | geen gegevens | |
| Vice Chairman | 3.7yrs | geen gegevens | geen gegevens | |
| Chairman of the Supervisors | 4.3yrs | geen gegevens | geen gegevens | |
| Employee Representative Supervisor | 2.6yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 1.9yrs | CN¥150.00k | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
2.4yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1066 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.